Daniel Carlat, MD

Non-Addictive, Pharmacological Options for Sleep

August 23, 2018

Daniel Carlat, MD Publisher, The Carlat Addiction Treatment Report Dr. Carlat has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this month’s interview with Dr. Eric Hermes, we learned about his approach to treating insomnia in patients with substance use disorders, with a focus on cognitive behavioral therapy. In this article, we’ll look at some non-addictive pharmacological options.

Note From the Editor-in-Chief

March 1, 2018

Daniel Carlat, MD

Daniel Carlat, MD Editor-in-Chief, The Carlat Psychiatry Report

We publish an issue on antipsychotics at least once a year, and it’s always a challenge to decide what to cover. There are dozens of antipsychotics, and most of them are approved for mood disorders as well as psychosis.

Medication Fact Book For Psychiatric Practice, Fourth Edition (2018)

PDF Access and CME Post-Test

February 28, 2018

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have disclosed that they has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Downloading your PDF and eBook copies and complete the CME Post-Test for The Medication Fact Book for Psychiatric Practice, Fourth Edition (2018).

Note From the Editor-in-Chief

February 1, 2018

Daniel Carlat, MD

Daniel Carlat, MD Editor-in-Chief, The Carlat Psychiatry Report

For this month’s issue, I asked two experts in family and couples therapy to remind us of how crucial it is to communicate with family members of patients. In the rush of a clinical day, it’s often easiest to simply deal with whomever shows up to the appointment—typically just the patient.

Note From the Editor-in-Chief

January 1, 2018

Daniel Carlat, MD

Daniel Carlat, MD Editor-in-Chief, The Carlat Psychiatry Report

When I was training in the 1990s, diagnosing bipolar disorder seemed straightforward. These patients often came to our attention because of a flagrant manic episode. You may still remember the first time you treated a manic patient—I certainly do.

Note From the Editor-in-Chief

December 1, 2017

Daniel Carlat, MD

Daniel Carlat, MD Editor-in-Chief, The Carlat Psychiatry Report.

My goal in publishing TCPR is to help you think differently about your clinical practice, hopefully to enhance your effectiveness as a healer. After editing this month’s issue on posttraumatic stress disorder (PTSD), I think I’ve achieved that goal in my own practice.

Update on Medications for PTSD

December 1, 2017

Robin Berlin, MD and Daniel Carlat, MD

Robin Berlin, MD Assistant clinical professor of psychiatry, George Washington University School of Medicine, and director of psychiatry, La Clinica del Pueblo, Washington, DC. Daniel Carlat, MD Editor-in-chief, The Carlat Psychiatry Report. Dr. Berlin and Dr. Carlat have disclosed that they have no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Every five years or so, we do an update on PTSD treatments; the most recent was our August 2011 issue of TCPR, in which we declared that psychotherapy was the gold standard for treatment.

Note From the Editor-in-Chief

November 1, 2017

Daniel Carlat, MD

Daniel Carlat, MD Editor-in-Chief

While I appreciate all of my TCPR subscribers, there’s one subscriber whom I value above all the others: my father. A psychiatrist who practices in the Bay Area, my father has been a loyal subscriber since Volume 1, Number 1, in January of 2003.

Note From the Editor-in-Chief

September 1, 2017

Daniel Carlat, MD

Daniel Carlat, MD Editor-in-Chief of TCPR

A welcome note from Editor-in-Chief and Publisher Daniel Carlat, MD, and a list of take home points from related to this special double issue.

Kratom: A Primer for Clinicians

September 1, 2017

Daniel Carlat, MD

Daniel Carlat, MD Editor-in-Chief, The Carlat Addiction Treatment Report Dr. Carlat has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Kratom (Mitagyna speciose) is a tropical evergreen tree in the coffee family whose leaves have been used for centuries in South Asian countries as a stimulant and pain reliever. Recently, kratom has entered US and European markets and is now sold in various forms, both online and at local head shops.